Vocabria tablets
通用名称
cabotegravir
儿科标签批准日期
2021/12/20 0:00:00
特定指示/秒
At-risk adults and adolescents weighing at least 35 kg for short-term pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection.
标签更改摘要
Treatment of HIV-1 Infection - Safety and efficacy have not been established in pediatric patients with HIV-1 infection. HIV-1 Pre-Exposure Prophylaxis - Safety and effectiveness of VOCABRIA for HIV-1 PrEP in at-risk adolescents weighing at least 35 kg is supported by data from 2 adequate and well-controlled trials of VOCABRIA for HIV-1 PrEP in adults with additional safety and pharmacokinetic data from studies in HIV-1 infected adults who were administered CABENUVA and in HIV-1 infected pediatric patients who were administered separate components of CABENUVA in addition to their current antiretroviral therapy. - APRETUDE for HIV-1 PrEP is being evaluated in 2 open-label multicenter clinical trials in adolescent individuals. Fifty-nine adolescents have been enrolled. Of these, 54 adolescent participants received one or more injections after receiving VOCABRIA. In adolescents receiving VOCABRIA and APRETUDE for HIV-1 PrEP, the safety data were comparable to the safety data reported in adults receiving APRETUDE for HIV-1 PrEP. - While using APRETUDE, HIV-1 testing should be conducted prior to initiating APRETUDE (with or without an oral lead-in with oral cabotegravir) and prior to each injection of APRETUDE. - Adolescents may benefit from more frequent visits and counseling to support adherence to the dosing schedule. - The safety, efficacy, and pharmacokinetics of VOCABRIA in pediatric participants younger than 12 years of age or weighing <35 kg have not been established. - Information on dosing, adverse reactions, PK parameters, and clinical studies. - New dosage form. - New indication. - Postmarketing studies.
治疗类别
Antivirals
立法类型
PREA + BPCA
产品说明书链接
免责声明:以上所展示的信息由企业自行提供,内容的真实性、准确性和合法性由发布企业负责,医药网对此不承担任何责任。
相关链接:国家药品监督管理局| 国家中医药管理局| SDA药品评审中心| 医加医疗器械| 膏药生产厂家| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究  客服热线:0575-83552251 / 13754370441  QQ客服:药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证:浙B2-20220931 互联网药品信息服务资格证书编号:(浙)-经营性2023-0215 浙公网安备:33068302000535
 医药代理商群1:药药网药品采购交流医药代理商群2:药药网药品采购交流2医药代理商群3:药药网药品采购交流3